CN1679870A - Quality control of compound Danshen root drops - Google Patents
Quality control of compound Danshen root drops Download PDFInfo
- Publication number
- CN1679870A CN1679870A CN 200510054696 CN200510054696A CN1679870A CN 1679870 A CN1679870 A CN 1679870A CN 200510054696 CN200510054696 CN 200510054696 CN 200510054696 A CN200510054696 A CN 200510054696A CN 1679870 A CN1679870 A CN 1679870A
- Authority
- CN
- China
- Prior art keywords
- rsd
- fufang danshen
- peaks
- danshen diwan
- peak area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 238000003908 quality control method Methods 0.000 title claims abstract description 28
- 244000132619 red sage Species 0.000 title claims abstract description 26
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000013068 control sample Substances 0.000 claims abstract description 13
- 239000008899 fufang danshen Substances 0.000 claims description 137
- 230000014759 maintenance of location Effects 0.000 claims description 111
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 86
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 51
- 238000007639 printing Methods 0.000 claims description 45
- 229960000583 acetic acid Drugs 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 239000000047 product Substances 0.000 claims description 41
- 239000012362 glacial acetic acid Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 33
- 229910021529 ammonia Inorganic materials 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000011010 flushing procedure Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 239000000945 filler Substances 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 15
- 240000007164 Salvia officinalis Species 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- 235000017276 Salvia Nutrition 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- -1 centrifugal standby Substances 0.000 claims description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 235000015096 spirit Nutrition 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 241000180649 Panax notoginseng Species 0.000 description 68
- 235000003143 Panax notoginseng Nutrition 0.000 description 67
- 239000003814 drug Substances 0.000 description 37
- 239000000126 substance Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 24
- 239000012071 phase Substances 0.000 description 24
- 239000000470 constituent Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 244000131316 Panax pseudoginseng Species 0.000 description 22
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 22
- 238000005303 weighing Methods 0.000 description 16
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 15
- 229930182494 ginsenoside Natural products 0.000 description 13
- 229940089161 ginsenoside Drugs 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012567 medical material Substances 0.000 description 9
- 239000007791 liquid phase Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 229930183118 Tanshinone Natural products 0.000 description 5
- 235000005412 red sage Nutrition 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 3
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 235000011158 Prunus mume Nutrition 0.000 description 2
- 244000018795 Prunus mume Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LJEROUHPDCFEGJ-VVTLTYDVSA-N (1r,3r,4s)-4,7,9-trihydroxy-1,3-dimethyl-3,4-dihydro-1h-benzo[g]isochromene-5,10-dione Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C2=C1[C@H](O)[C@@H](C)O[C@@H]2C LJEROUHPDCFEGJ-VVTLTYDVSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000012364 Peperomia pellucida Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 description 1
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Abstract
Description
????Time | ??A:0.01%HAC-H2O(%)(v/v) | ??B:0.01%HAC-CH3CN(%)(v/v) |
????0 ????15 ????25 ????40 ????50 ????65 ????75 | ????80 ????65 ????65 ????57 ????57 ????42 ????25 | ????20 ????35 ????35 ????43 ????43 ????58 ????75 |
Peak 1- | Peak 2- | Peak 3- | Peak 4- | Peak 5- | Peak 6- | Peak 7- |
Panax Notoginseng saponin R 1 | Ginsenoside R e+R g1 | Ginsenoside R b1 | Panax Notoginseng saponin R 2 | Ginsenoside R h1 | Ginsenoside Rh liso. (F1) | Ginsenoside R d |
Peak 8- | Peak 9- | Peak 10- | Peak 11- | Peak 12- | Peak 13- | Peak 14- |
Panax Notoginseng saponin R 2-H2O | Panax Notoginseng saponin R 2-H2O | Ginsenoside R g6/F 4 | Ginsenoside R k3/R h4(R k3) | Ginsenoside R k3/R h4(R h4) | Ginsenoside R k1/R g5(R k1) | Ginsenoside R k1/R g5(R g5) |
Peak number | Average retention time | The RSD% of retention time | Average peak area | The RSD% of peak area | The unimodal percentage ratio that accounts for total peak area |
????1 | ????10.85 | ????0.08 | ??557.29 | ????15.67 | ????5.36% |
????2 | ????12.1 | ????0.06 | ??2728.83 | ????16.66 | ????26.23% |
????3 | ????20.33 | ????0.08 | ??3704.31 | ????14.15 | ????35.61% |
????4 | ????20.86 | ????0.07 | ??272.69 | ????12.54 | ????2.62% |
????5 | ????23.28 | ????0.08 | ??369.12 | ????21.52 | ????3.55% |
????6 | ????24.48 | ????0.08 | ??190.23 | ????17.45 | ????1.83% |
????7 | ????28.82 | ????1.36 | ??289.16 | ????17.71 | ????2.78% |
????8 | ????42.93 | ????0.07 | ??239.14 | ????18.84 | ????2.30% |
????9 | ????45.66 | ????0.06 | ??445.17 | ????19.56 | ????4.28% |
????10 | ????47.85 | ????0.06 | ??723.59 | ????14.24 | ????6.96% |
????11 | ????68.17 | ????0.03 | ??407.66 | ????10.86 | ????3.92% |
????12 | ????69.4 | ????0.03 | ??476.31 | ????15.46 | ????4.58% |
Peak number | Average retention time | Retention time RSD% | Average peak area | Peak area RSD% | The unimodal percentage ratio that accounts for total peak area |
????1 | ????10.87 | ????0.45 | ??506.92 | ????13.03 | ????4.27% |
????2 | ????12.12 | ????0.34 | ??2723.73 | ????12.11 | ????22.93% |
????3 | ????20.34 | ????0.23 | ??1684.49 | ????18.95 | ????14.18% |
????4 | ????20.86 | ????0.16 | ??231.84 | ????18.99 | ????1.95% |
????5 | ????23.29 | ????0.25 | ??565.78 | ????13.8 | ????4.76% |
????6 | ????24.48 | ????0.28 | ??309.39 | ????18.98 | ????2.60% |
????7 | ????29 | ????0.62 | ??345.32 | ????14.28 | ????2.91% |
????8 | ????41.21 | ????0.25 | ??436.06 | ????10.88 | ????3.67% |
????9 | ????42.94 | ????0.21 | ??665.38 | ????11.82 | ????5.60% |
????10 | ????44.16 | ????0.21 | ??472.84 | ????14.59 | ????3.98% |
????11 | ????45.68 | ????0.23 | ??947.39 | ????16.06 | ????7.97% |
????12 | ????47.88 | ????0.25 | ??1547.8 | ????13.25 | ????13.03% |
????13 | ????68.21 | ????0.13 | ??622.91 | ????10.39 | ????5.24% |
????14 | ????69.43 | ????0.12 | ??820.24 | ????12.93 | ????6.90% |
????Time | ??A:0.01%HAC-H2O(%) | ??B:0.01%HAC-CH3CN(%) |
????0 ????15 ????25 ????40 ????50 ????65 ????75 | ????80 ????65 ????65 ????57 ????57 ????42 ????25 | ????20 ????35 ????35 ????43 ????43 ????58 ????75 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100546967A CN100381813C (en) | 2004-03-16 | 2005-03-16 | Quality control of compound Danshen root drops |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410018749 | 2004-03-16 | ||
CN200410018749.5 | 2004-03-16 | ||
CNB2005100546967A CN100381813C (en) | 2004-03-16 | 2005-03-16 | Quality control of compound Danshen root drops |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679870A true CN1679870A (en) | 2005-10-12 |
CN100381813C CN100381813C (en) | 2008-04-16 |
Family
ID=35066876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100546967A Active CN100381813C (en) | 2004-03-16 | 2005-03-16 | Quality control of compound Danshen root drops |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100381813C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100442049C (en) * | 2004-03-17 | 2008-12-10 | 天津天士力制药股份有限公司 | Method for measuring fingerprint pattern of compound salvia dropping pills |
CN108333282A (en) * | 2018-04-24 | 2018-07-27 | 山东农业大学 | A kind of method of a variety of phenolic acid class and tanshinone component in Rapid Simultaneous Determination Fufang Danshen Pian |
CN109196354A (en) * | 2016-05-30 | 2019-01-11 | 株式会社岛津制作所 | Chromatogram arrangement |
CN111487350A (en) * | 2020-05-18 | 2020-08-04 | 陕西中医药大学 | Quality detection method of salvia miltiorrhiza-panax notoginseng medicine pair |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1472532A (en) * | 2002-08-02 | 2004-02-04 | 上海蔡同德堂中药制药厂 | Method for determining salviolic acid beta content in red sage root |
CN100412545C (en) * | 2002-12-23 | 2008-08-20 | 北京采瑞医药有限公司 | Method for controlling quality of compound red sage root preparation used for treating cardio-cerebral vascualr disease |
-
2005
- 2005-03-16 CN CNB2005100546967A patent/CN100381813C/en active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100442049C (en) * | 2004-03-17 | 2008-12-10 | 天津天士力制药股份有限公司 | Method for measuring fingerprint pattern of compound salvia dropping pills |
CN109196354A (en) * | 2016-05-30 | 2019-01-11 | 株式会社岛津制作所 | Chromatogram arrangement |
CN108333282A (en) * | 2018-04-24 | 2018-07-27 | 山东农业大学 | A kind of method of a variety of phenolic acid class and tanshinone component in Rapid Simultaneous Determination Fufang Danshen Pian |
CN111487350A (en) * | 2020-05-18 | 2020-08-04 | 陕西中医药大学 | Quality detection method of salvia miltiorrhiza-panax notoginseng medicine pair |
Also Published As
Publication number | Publication date |
---|---|
CN100381813C (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101036748A (en) | Quality control method of the Yixinshu Chinese traditional medicine for supplementing qi and for promoting blood circulation by removing blood stasis | |
CN1895617A (en) | Kidney-warming and heart-nourishing Chinese-medicinal preparation, its making method and quality control | |
CN1669573A (en) | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
CN1670529A (en) | Method for constructing Compound Xueshuantong preparation HPLC fingerprint pattern and method standard fingerprint pattern thereof | |
CN1903250A (en) | Method for extraction and separation of red rooted salvia | |
CN101073587A (en) | Method for separating and extracting Chinese Thorowax Root | |
CN1857434A (en) | Qulity control method for new compound isatis leaf preparation | |
CN1857642A (en) | Quality control method for depression relieving and tranquilizing preparation | |
CN1903239A (en) | Method for extraction and separation of rhizome of chuanixong | |
CN1785380A (en) | Quality control method of Chinese medicinal preparation | |
CN1843425A (en) | Dispersion tablet for getting brain and heart unobstructed and preparation method and its quality control method | |
CN101073623A (en) | Method for separating and extracting cattail pollen | |
CN1679870A (en) | Quality control of compound Danshen root drops | |
CN1876089A (en) | A pharmaceutical composition for treating kidney-qi deficiency syndrome and preparation method thereof | |
CN1872199A (en) | Composition of Chinese traditional medicine, and preparation method | |
CN1785281A (en) | Quality control method of spirit quieting oral liquid preparation | |
CN1670524A (en) | Method for measuring fingerprint pattern of compound salvia dropping pills | |
CN1679871A (en) | Quality control of compound Danshen root drops | |
CN100345555C (en) | Pain-relieving | |
CN1785347A (en) | Quality control method of Chinese medicinal preparation for treating child hyperpyrexia | |
CN1679811A (en) | Danshen root extract, production, medicine preparation and inspection thereof | |
CN1511583A (en) | Chinese rose extract and its preparing method and use | |
CN1670525A (en) | Method for measuring fingerprint pattern of compound salvia dropping pills | |
CN1857588A (en) | Quality control method for Xianlinggubao preparation | |
CN101066437A (en) | Quality control method for compound cantharis oral liquid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENG YIYU; APPLICANT Effective date: 20070601 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070601 Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: 310000, room 72, No. 15, Qiushi village, Xihu District, Zhejiang, Hangzhou 103, China Applicant before: Cheng Yiyu Co-applicant before: Ye Zhengliang Co-applicant before: Zheng Yongfeng |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |